JP6095984B2 - Ｈｃｖ感染患者のクリオグロブリン血症性血管炎およびｂ細胞悪性腫瘍のための予後マーカー - Google Patents
Ｈｃｖ感染患者のクリオグロブリン血症性血管炎およびｂ細胞悪性腫瘍のための予後マーカー Download PDFInfo
- Publication number
- JP6095984B2 JP6095984B2 JP2012556133A JP2012556133A JP6095984B2 JP 6095984 B2 JP6095984 B2 JP 6095984B2 JP 2012556133 A JP2012556133 A JP 2012556133A JP 2012556133 A JP2012556133 A JP 2012556133A JP 6095984 B2 JP6095984 B2 JP 6095984B2
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- xid
- cells
- patients
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 210000003719 b-lymphocyte Anatomy 0.000 title claims description 98
- 201000003278 cryoglobulinemia Diseases 0.000 title claims description 69
- 206010047115 Vasculitis Diseases 0.000 title claims description 54
- 206010028980 Neoplasm Diseases 0.000 title claims description 44
- 230000036210 malignancy Effects 0.000 title claims description 42
- 241000711549 Hepacivirus C Species 0.000 claims description 102
- 238000000034 method Methods 0.000 claims description 45
- 208000024891 symptom Diseases 0.000 claims description 37
- 208000015181 infectious disease Diseases 0.000 claims description 36
- 239000008280 blood Substances 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 20
- 108090000623 proteins and genes Proteins 0.000 claims description 19
- 108060003951 Immunoglobulin Proteins 0.000 claims description 17
- 102000018358 immunoglobulin Human genes 0.000 claims description 17
- 150000007523 nucleic acids Chemical group 0.000 claims description 15
- 102100022297 Integrin alpha-X Human genes 0.000 claims description 10
- 208000010710 hepatitis C virus infection Diseases 0.000 claims description 10
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 108010004729 Phycoerythrin Proteins 0.000 claims description 8
- 210000004027 cell Anatomy 0.000 claims description 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 7
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 claims description 7
- 210000004602 germ cell Anatomy 0.000 claims description 7
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 238000000684 flow cytometry Methods 0.000 claims description 5
- 108020004707 nucleic acids Proteins 0.000 claims description 4
- 102000039446 nucleic acids Human genes 0.000 claims description 4
- 101100341519 Homo sapiens ITGAX gene Proteins 0.000 claims description 3
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 108091035707 Consensus sequence Proteins 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 18
- 210000004698 lymphocyte Anatomy 0.000 description 17
- 108010091326 Cryoglobulins Proteins 0.000 description 16
- 201000010099 disease Diseases 0.000 description 15
- 208000005176 Hepatitis C Diseases 0.000 description 14
- 238000001514 detection method Methods 0.000 description 13
- 206010016654 Fibrosis Diseases 0.000 description 9
- 206010025323 Lymphomas Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 7
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 7
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 7
- 230000007882 cirrhosis Effects 0.000 description 7
- 208000019425 cirrhosis of liver Diseases 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 230000018109 developmental process Effects 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 229920002477 rna polymer Polymers 0.000 description 7
- 208000006154 Chronic hepatitis C Diseases 0.000 description 6
- 206010061818 Disease progression Diseases 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 230000005750 disease progression Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000013399 early diagnosis Methods 0.000 description 5
- 229940027941 immunoglobulin g Drugs 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 4
- 238000012300 Sequence Analysis Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000037390 scarring Effects 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 208000037581 Persistent Infection Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000004732 Systemic Vasculitis Diseases 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 208000017169 kidney disease Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 208000033808 peripheral neuropathy Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 206010065051 Acute hepatitis C Diseases 0.000 description 2
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 2
- 108010082126 Alanine transaminase Proteins 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 2
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 2
- 208000037914 B-cell disorder Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 101710091045 Envelope protein Proteins 0.000 description 2
- 101001037147 Homo sapiens Immunoglobulin heavy variable 1-69 Proteins 0.000 description 2
- 101001047618 Homo sapiens Immunoglobulin kappa variable 3-15 Proteins 0.000 description 2
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 2
- 102100040232 Immunoglobulin heavy variable 1-69 Human genes 0.000 description 2
- 102100022965 Immunoglobulin kappa variable 3-15 Human genes 0.000 description 2
- 102100022964 Immunoglobulin kappa variable 3-20 Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022004 Influenza like illness Diseases 0.000 description 2
- 102000006992 Interferon-alpha Human genes 0.000 description 2
- 108010047761 Interferon-alpha Proteins 0.000 description 2
- 206010023126 Jaundice Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 102100021696 Syncytin-1 Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 208000037621 acute hepatitis C virus infection Diseases 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 238000009534 blood test Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001605 fetal effect Effects 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000000405 serological effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 101150084750 1 gene Proteins 0.000 description 1
- 101150090724 3 gene Proteins 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- 108091093088 Amplicon Proteins 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 1
- 101150019496 IGHV1-69 gene Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010056872 Palpable purpura Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 238000010802 RNA extraction kit Methods 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000004594 appetite change Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 229940125691 blood product Drugs 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 201000000564 macroglobulinemia Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 208000007232 portal hypertension Diseases 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/328—Vasculitis, i.e. inflammation of blood vessels
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30916110P | 2010-03-01 | 2010-03-01 | |
| US61/309,161 | 2010-03-01 | ||
| PCT/US2011/026455 WO2011109285A2 (en) | 2010-03-01 | 2011-02-28 | Prognostic marker for cryoglobulinemic vasculitis and b cell malignancies in hcv infected patients |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013521497A JP2013521497A (ja) | 2013-06-10 |
| JP2013521497A5 JP2013521497A5 (enExample) | 2014-04-24 |
| JP6095984B2 true JP6095984B2 (ja) | 2017-03-15 |
Family
ID=44542788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012556133A Expired - Fee Related JP6095984B2 (ja) | 2010-03-01 | 2011-02-28 | Ｈｃｖ感染患者のクリオグロブリン血症性血管炎およびｂ細胞悪性腫瘍のための予後マーカー |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US9719141B2 (enExample) |
| EP (1) | EP2542892A4 (enExample) |
| JP (1) | JP6095984B2 (enExample) |
| AU (1) | AU2011223906B2 (enExample) |
| BR (1) | BR112012021795A2 (enExample) |
| CA (1) | CA2791676A1 (enExample) |
| WO (1) | WO2011109285A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103184216B (zh) * | 2011-12-27 | 2015-03-18 | 深圳华大基因科技有限公司 | 用于扩增免疫球蛋白重链cdr3编码序列的引物组合物及其用途 |
| US11781112B2 (en) | 2016-03-06 | 2023-10-10 | Kareem Thomas Robinson | Method of generating antigen-specific immunological memory in a subject that rejects classical vaccines |
| RU2642626C1 (ru) * | 2016-11-03 | 2018-01-25 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Способ прогнозирования развития криоглобулинемического васкулита у больных хроническим гепатитом с |
| EP3665705B1 (en) | 2017-08-08 | 2024-12-18 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20020049A1 (it) | 2002-01-30 | 2003-07-30 | Biostrands S R L | Frammenti fab di anticorpi monoclonali umani diretti contro la glicoproteina e2 di hcv e dotati di potere neutralizzante in vitro. |
| US8178303B2 (en) | 2003-12-04 | 2012-05-15 | Wake Forest University Health Sciences | Increasing the speed of cryoglobulin precipitation |
| EP1801116A1 (en) | 2005-12-21 | 2007-06-27 | F. Hoffmann-La Roche Ag | HCV replicon shuttle vectors |
-
2011
- 2011-02-28 CA CA2791676A patent/CA2791676A1/en not_active Abandoned
- 2011-02-28 WO PCT/US2011/026455 patent/WO2011109285A2/en not_active Ceased
- 2011-02-28 JP JP2012556133A patent/JP6095984B2/ja not_active Expired - Fee Related
- 2011-02-28 BR BR112012021795A patent/BR112012021795A2/pt not_active IP Right Cessation
- 2011-02-28 US US13/581,759 patent/US9719141B2/en not_active Expired - Fee Related
- 2011-02-28 AU AU2011223906A patent/AU2011223906B2/en not_active Ceased
- 2011-02-28 EP EP11751140.2A patent/EP2542892A4/en not_active Withdrawn
-
2015
- 2015-09-23 US US14/863,220 patent/US20160083801A1/en not_active Abandoned
-
2017
- 2017-09-11 US US15/701,379 patent/US20180002763A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20160083801A1 (en) | 2016-03-24 |
| EP2542892A4 (en) | 2013-11-27 |
| CN102859360A (zh) | 2013-01-02 |
| AU2011223906A1 (en) | 2012-09-13 |
| US20180002763A1 (en) | 2018-01-04 |
| WO2011109285A2 (en) | 2011-09-09 |
| CA2791676A1 (en) | 2011-09-09 |
| EP2542892A2 (en) | 2013-01-09 |
| JP2013521497A (ja) | 2013-06-10 |
| WO2011109285A3 (en) | 2012-01-19 |
| US20130052206A1 (en) | 2013-02-28 |
| BR112012021795A2 (pt) | 2016-05-17 |
| AU2011223906B2 (en) | 2015-06-25 |
| US9719141B2 (en) | 2017-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Persico et al. | Hepatitis C virus carriers with persistently normal ALT levels: biological peculiarities and update of the natural history of liver disease at 10 years | |
| CN104160039B (zh) | 川崎病的生物标志物 | |
| US20180002763A1 (en) | Prognostic Marker For Cryoglobulinemic Vasculitis And B Cell Malignancies In HCV Infected Patients | |
| CN116983413A (zh) | Plekhh2在肺动脉高压诊断和治疗方面的应用 | |
| Ramesh et al. | The role of myositis-specific autoantibodies in the dermatomyositis spectrum | |
| WO2017175228A1 (en) | Infiltrating immune cell proportions predict anti-tnf response in colon biopsies | |
| Knight et al. | Detection of WA B cells in hepatitis C virus infection: a potential prognostic marker for cryoglobulinemic vasculitis and B cell malignancies | |
| De Almeida et al. | Autoimmune thrombocytopenia related to chronic hepatitis C virus infection | |
| US10584387B2 (en) | Detection of hepatitis delta virus (HDV) for the diagnosis and treatment of Sjögren's syndrome and lymphoma | |
| Xian et al. | Potential involvement of M1 macrophage and VLA4/VCAM-1 pathway in the valvular damage due to rheumatic heart disease | |
| JP2013021932A (ja) | 関節リウマチに対する抗ｉｌ−６受容体抗体療法の有効性の予測方法 | |
| JP2013521497A5 (enExample) | ||
| JPWO2017159771A1 (ja) | 肝細胞増殖因子（ｈｇｆ）のｐｄマーカー | |
| CN102859360B (zh) | Hcv感染患者中的冷球蛋白血症性血管炎和b细胞恶性肿瘤的预测标志物 | |
| WO2020167715A1 (en) | Biomarkers of progressive multifocal leukoencephalopathy | |
| KR20250068724A (ko) | Hbv 진단학적, 예후적 및 치료학적 방법 및 생성물 | |
| JP2024005979A (ja) | 肉芽腫または肉芽腫を伴う疾患を処置および／または予防するための組成物および対象が肉芽腫を有するか否かを判定するための方法およびキット | |
| US20040073006A1 (en) | Antibody against norwalk virus and method of detecting virus by using the antibody | |
| CN116144765A (zh) | 生物标志物plxnc1在结直肠癌诊断、治疗和预后预测中的应用 | |
| El Awady et al. | Circulating viral core and E1 antigen levels as supplemental markers for HCV chronic hepatitis | |
| CN111440870A (zh) | CircZCCHC11及其翻译的肽段在肿瘤生长和转移预测、预后评估和治疗中的应用 | |
| JP4958773B2 (ja) | Ｃ型肝炎ウイルス感染の診断、予防および治療方法 | |
| Hammad et al. | T-cytotoxic Expression of Leukocyte-Associated Immunoglobulin-like Receptor-1 (LAIR-1) in post-HCV Hepatocellular Carcinoma | |
| KR101968962B1 (ko) | 비만 저항성 진단용 조성물 | |
| Shalek | A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140228 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140228 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150407 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150703 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150806 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150907 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20151124 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160324 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20160602 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160726 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160915 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170117 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170215 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6095984 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |